SOPH
SOPHiA GENETICS S.A.
NASDAQ · Healthcare · Medical - Healthcare Information Services · CH
$8.14
−1.93%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.9x
Market Cap
$692.94M
MomentumView details →
1D Return
−1.93%
YTD Return
+74.20%
RSI (14)
56.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.9x
Market Cap
$692.94M
RSI (14)
56.9
MomentumView details →
1D Return
−1.93%
YTD Return
+74.20%
SummaryUpdated Jun 1, 2026
SOPHiA GENETICS SA (NASDAQ:SOPH) is a Swiss healthcare technology company founded in 2011 and headquartered in Saint-Sulpice, Switzerland. The company went public in July 2021, positioning itself as a leader in data-driven medicine through artificial intelligence and cloud computing. SOPHiA GENETICS has built a global platform that serves hospitals, laboratories, and biopharmaceutical companies across more than 70 countries, with nearly 800 healthcare institutions using its technology to analyze genomic data for precision medicine applications.
Similar companies
Latest newsMore news →
SOPHiA GENETICS reported financial results for the second quarter ended June 30, 2026, with revenue of $23.3 million, up 27% year-over-year, and a net loss of $22.4 million.31d agoSOPHiA GENETICS announced a global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies.31d ago